Logo image of QCLS

Q/C TECHNOLOGIES INC (QCLS) Stock Fundamental Analysis

USA - NASDAQ:QCLS - US62856X2018 - Common Stock

3.89 USD
+0.21 (+5.71%)
Last: 10/13/2025, 8:00:02 PM
3.8 USD
-0.09 (-2.31%)
Pre-Market: 10/14/2025, 7:24:50 AM
Fundamental Rating

1

QCLS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. QCLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. QCLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year QCLS has reported negative net income.
QCLS had a negative operating cash flow in the past year.
QCLS had negative earnings in each of the past 5 years.
In the past 5 years QCLS always reported negative operating cash flow.
QCLS Yearly Net Income VS EBIT VS OCF VS FCFQCLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

Looking at the Return On Assets, with a value of -61.38%, QCLS is doing worse than 65.64% of the companies in the same industry.
With a Return On Equity value of -90.74%, QCLS perfoms like the industry average, outperforming 42.05% of the companies in the same industry.
Industry RankSector Rank
ROA -61.38%
ROE -90.74%
ROIC N/A
ROA(3y)-86.48%
ROA(5y)-85.52%
ROE(3y)-117.42%
ROE(5y)-105.9%
ROIC(3y)N/A
ROIC(5y)N/A
QCLS Yearly ROA, ROE, ROICQCLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

QCLS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
QCLS Yearly Profit, Operating, Gross MarginsQCLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

4

2. Health

2.1 Basic Checks

QCLS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, QCLS has more shares outstanding
There is no outstanding debt for QCLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
QCLS Yearly Shares OutstandingQCLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
QCLS Yearly Total Debt VS Total AssetsQCLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -11.78, we must say that QCLS is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -11.78, QCLS is not doing good in the industry: 73.85% of the companies in the same industry are doing better.
QCLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.78
ROIC/WACCN/A
WACCN/A
QCLS Yearly LT Debt VS Equity VS FCFQCLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

QCLS has a Current Ratio of 0.93. This is a bad value and indicates that QCLS is not financially healthy enough and could expect problems in meeting its short term obligations.
QCLS has a Current ratio of 0.93. This is amonst the worse of the industry: QCLS underperforms 84.10% of its industry peers.
A Quick Ratio of 0.93 indicates that QCLS may have some problems paying its short term obligations.
The Quick ratio of QCLS (0.93) is worse than 75.90% of its industry peers.
Industry RankSector Rank
Current Ratio 0.93
Quick Ratio 0.93
QCLS Yearly Current Assets VS Current LiabilitesQCLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for QCLS have decreased strongly by -449.92% in the last year.
EPS 1Y (TTM)-449.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-289.01%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
QCLS Yearly Revenue VS EstimatesQCLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 1M 2M 3M 4M 5M
QCLS Yearly EPS VS EstimatesQCLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2017 -500K -1M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for QCLS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
QCLS Price Earnings VS Forward Price EarningsQCLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
QCLS Per share dataQCLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for QCLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Q/C TECHNOLOGIES INC

NASDAQ:QCLS (10/13/2025, 8:00:02 PM)

Premarket: 3.8 -0.09 (-2.31%)

3.89

+0.21 (+5.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-18 2025-08-18
Earnings (Next)11-12 2025-11-12
Inst Owners0.29%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change99.65%
Market Cap7.20M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.5
Dividend Growth(5Y)N/A
DP-2.12%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.62
P/tB 6.53
EV/EBITDA N/A
EPS(TTM)-56.09
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.92
FCFYN/A
OCF(TTM)-4.92
OCFYN/A
SpS0
BVpS6.27
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.38%
ROE -90.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-86.48%
ROA(5y)-85.52%
ROE(3y)-117.42%
ROE(5y)-105.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.93
Quick Ratio 0.93
Altman-Z -11.78
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-449.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-289.01%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y43.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.03%
OCF growth 3YN/A
OCF growth 5YN/A